87,500 Shares in Celgene Co. (CELG) Acquired by Water Island Capital LLC

Water Island Capital LLC purchased a new stake in Celgene Co. (NASDAQ:CELG) during the 1st quarter, Holdings Channel reports. The fund purchased 87,500 shares of the biopharmaceutical company’s stock, valued at approximately $8,255,000.

A number of other institutional investors have also made changes to their positions in CELG. Neuberger Berman Group LLC grew its holdings in Celgene by 2.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 408,133 shares of the biopharmaceutical company’s stock valued at $36,524,000 after purchasing an additional 10,316 shares in the last quarter. Morgan Stanley grew its holdings in Celgene by 20.4% during the 3rd quarter. Morgan Stanley now owns 3,236,323 shares of the biopharmaceutical company’s stock valued at $289,620,000 after purchasing an additional 549,404 shares in the last quarter. Federated Investors Inc. PA grew its holdings in Celgene by 9.8% during the 3rd quarter. Federated Investors Inc. PA now owns 304,970 shares of the biopharmaceutical company’s stock valued at $27,291,000 after purchasing an additional 27,284 shares in the last quarter. First Citizens Bank & Trust Co. grew its holdings in Celgene by 816.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 28,745 shares of the biopharmaceutical company’s stock worth $1,842,000 after acquiring an additional 25,609 shares in the last quarter. Finally, RPG Investment Advisory LLC grew its holdings in Celgene by 1.5% during the 4th quarter. RPG Investment Advisory LLC now owns 80,733 shares of the biopharmaceutical company’s stock worth $5,174,000 after acquiring an additional 1,167 shares in the last quarter. 71.71% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene stock traded up $0.20 during trading hours on Friday, reaching $95.71. The company’s stock had a trading volume of 166,278 shares, compared to its average volume of 5,071,124. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78. Celgene Co. has a one year low of $58.59 and a one year high of $97.07. The company has a market cap of $67.07 billion, a P/E ratio of 12.59, a PEG ratio of 0.43 and a beta of 1.68.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. During the same period last year, the firm posted $2.05 EPS. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. As a group, sell-side analysts predict that Celgene Co. will post 9.85 earnings per share for the current year.

Several research analysts have weighed in on the stock. BidaskClub lowered shares of Celgene from a “hold” rating to a “sell” rating in a report on Thursday, April 25th. Barclays lowered shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price objective for the company. in a report on Friday, May 3rd. ValuEngine raised shares of Celgene from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Mizuho reissued a “buy” rating and set a $103.00 price objective on shares of Celgene in a report on Thursday. Finally, Atlantic Securities lowered shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 price objective for the company. in a report on Monday, April 1st. Twenty investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $95.96.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/17/87500-shares-in-celgene-co-celg-acquired-by-water-island-capital-llc.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Google Finance

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.